Vericel Corp(VCEL) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 7:00 AM ET (Korea 9/11 20:00)
Full metrics table
| Index | RUT | P/E | 81.93 | EPS (ttm) | 0.46 | Insider Own | 1.2% | Shs Outstand | 51.2M | Perf Week | -7.39% |
| Market Cap | 1.94B | Forward P/E | 43.77 | EPS next Y | 61.9% | Insider Trans | -17.34% | Shs Float | 50.6M | Perf Month | -14.61% |
| Enterprise Value | 1.87B | PEG | 0.72 | EPS next Q | 0.06 | Inst Own | 109.09% | Short Float | 9.34% | Perf Quarter | 1.31% |
| Income | 0.02B | P/S | 6.33 | EPS this Y | 67.01% | Inst Trans | 0.29% | Short Ratio | 8.44 | Perf Half Y | 15.18% |
| Sales | 0.31B | P/B | 5.24 | EPS next 5Y | 61.02% | ROA | 5.16% | Short Interest | 4.72M | Perf YTD | 5.17% |
| Book/sh | 7.23 | P/C | 11.94 | EPS past 3/5Y | - 39.2% | ROE | 7.16% | 52W High | -23.22% ($49.32) | Perf Year | 20.95% |
| Cash/sh | 3.17 | P/FCF | 31.45 | Sales past 3/5Y | 18.9% 17.34% | ROIC | 5.38% | 52W Low | 30.81% ($28.95) | Perf 3Y | 15.77% |
| Dividend Est. | - | EV/EBITDA | 60.07 | EPS Y/Y TTM | 228.76% | Gross Margin | 74.56% | Volatility(W/M) | 2.38% 3.19% | Perf 5Y | -26.65% |
| Dividend TTM | - | EV/Sales | 6.11 | Sales Y/Y TTM | 22.95% | Oper. Margin | 5.95% | ATR (14) | 1.37 | Perf 10Y | 1621.36% |
| Dividend Ex-Date | - | Quick Ratio | 4.69 | EPS Q/Q | 483.64% | Profit Margin | 7.91% | RSI (14) | 27.46 | Recom | 1.25 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.04 | Sales Q/Q | 22.48% | SMA20 | -9.07% ($41.65) | Beta | 1.03 | Target Price | $60.57 |
| Payout | - | Debt/Eq | 0.26 | Earnings | 2026/7/30 | SMA50 | -14.52% ($44.3) | Rel Volume | 0.61 | Prev Close | $38.99 |
| Employees | 398 | LT Debt/Eq | 0.22 | EPS/Sales Surpr. | 238.41% 6.54% | SMA200 | -0.75% ($38.16) | Avg Volume(3M) | 0.56M | Price | $37.87 |
| IPO | 1997/2/4 | Option/Short | Yes/Yes | Trades | 8910 | Volume | 340,237 | Change | -2.87% |
Company
VCEL is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
A US biotech company that develops and commercializes cell therapy and regenerative medicine products. It markets and supplies cartilage regeneration therapies using patients' own cells, skin cell therapies for severe burns, and burn treatment products, with a focus on sports medicine and burn care. The company has established itself as a biotech player with a commercialized portfolio of cell therapy and regenerative medicine products.
Over the past 1 year, roughly in the middle
23% below its 1-year high.
VCEL makes money exceptionally well
5.95% of revenue is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +67.0% this year.
Tap to view numbers
But it is not cheap
Trading at 81.9 times earnings.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 3 quarters.
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by +15.8% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 109.1%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
PBE 0.03%
SBIO 0.01%
PSCH 0.01%
YUNG 0.01%
MATE 0.01%It ranks #4 in the industry
Based on market cap of $2B.
VCEL $2B PER 81.9
VRTX $130B PER 29.9
REGN $82B PER 19.6
ARGX $62B PER 37.5
FAQ
What kind of company is VCEL?
VCEL belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of VCEL?
The market cap of VCEL is approximately $1.9B, ranking 2,128 within its sector.
What is the P/E ratio of VCEL?
VCEL has a P/E ratio of approximately 81.9x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for VCEL?
VCEL has recorded a 52-week high of $49.32 and a low of $28.95.
